Synergistic Approach of Antibody-Photosensitizer Conjugate Independent of KRAS-Mutation and Its Downstream Blockade Pathway in Colorectal Cancer

被引:10
作者
Ahn, Minji [1 ,2 ]
Lee, Taebum [1 ,2 ]
Kim, Kyoung Sub [2 ]
Lee, Sanghee [3 ]
Na, Kun [1 ,2 ]
机构
[1] Catholic Univ Korea, Dept Biomed Chem Engn, 43 Jibong Ro, Bucheon Si 14662, Gyeonggi Do, South Korea
[2] Catholic Univ Korea, Dept Biotechnol, 43 Jibong Ro, Bucheon Si 14662, Gyeonggi Do, South Korea
[3] Northwestern Univ, Feinberg Sch Med, Dept Radiol, Chicago, IL 60611 USA
基金
新加坡国家研究基金会;
关键词
antibody drug conjugates; cetuximab conjugates; KRAS mutation; linker chemistry; photoimmunotherapy; EGFR-TARGETED THERAPIES; DRUG; RESISTANCE; CETUXIMAB; LINKERS;
D O I
10.1002/adhm.202302374
中图分类号
R318 [生物医学工程];
学科分类号
0831 ;
摘要
Here, a novel approach is presented to improve the efficacy of antibody-drug conjugates (ADC) by integrating antibody-mediated immunotherapy and photodynamic therapy (PDT) in a combination therapy system utilizing an antibody-photosensitizer conjugate (APC) platform based on a poloxamer polymer linker. To specifically target Kirsten rat sarcoma 2 viral oncogene homolog (KRAS)-mutated cancer cells, an antibody antiepidermal growth factor receptor (EGFR), cetuximab, with a poloxamer linker coupled with the photosensitizer chlorin e6 through click chemistry (cetuximab-maleimide-poly(ethylene oxide)-poly(propylene oxide)-poly(ethylene oxide)-chlorine e6 conjugate, CMPXC) is synthesized. CMPXC is cytotoxic upon laser treatment, achieving a 90% cell death by suppressing KRAS downstream signaling pathways associated with ERK and AKT proteins, confirmed using RNA sequencing analysis. In KRAS-mutated colorectal cancer mouse models, CMPXC significantly enhances antitumor efficacy compared with cetuximab treatment alone, resulting in an 86% reduction in tumor growth. Furthermore, CMPXC treatment leads to a 2.24- and 1.75-fold increase in dendritic and priming cytotoxic T cells, respectively, highlighting the immune-activating potential of this approach. The findings suggest that the APC platform addresses the challenges associated with ADC development and EGFR-targeted therapy, including the synergistic advantages of antibody-mediated immunotherapy and PDT. To improve the efficacy of antibody-drug conjugates, a novel platform by combining antibody-mediated immunotherpay and photodynamic therapy is constructed. Upon spatiotemporal light exposure, the antibody-photosensitizer conjugate exhibits a remarkable anticancer effect, independent Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) mutation, by suppressing KRAS downstream signaling pathways and providing innate and adaptive immune system induction through a synergistic approach.image
引用
收藏
页数:12
相关论文
共 49 条
[1]   Targeting immunogenic cancer cell death by photodynamic therapy: past, present and future [J].
Alzeibak, Razan ;
Mishchenko, Tatiana A. ;
Shilyagina, Natalia Y. ;
Balalaeva, Irina V. ;
Vedunova, Maria V. ;
Krysko, Dmitri V. .
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 (01)
[2]   Strategies and challenges for the next generation of antibody drug conjugates [J].
Beck, Alain ;
Goetsch, Liliane ;
Dumontet, Charles ;
Corvaia, Nathalie .
NATURE REVIEWS DRUG DISCOVERY, 2017, 16 (05) :315-337
[3]   Antibody-drug conjugates Present and future [J].
Beck, Alain ;
Reichert, Janice M. .
MABS, 2014, 6 (01) :15-17
[4]   Impact of Payload Hydrophobicity on the Stability of Antibody-Drug Conjugates [J].
Buecheler, Jakob W. ;
Winzer, Matthias ;
Tonillo, Jason ;
Weber, Christian ;
Gieseler, Henning .
MOLECULAR PHARMACEUTICS, 2018, 15 (07) :2656-2664
[5]   Photodynamic therapy and anti-tumour immunity [J].
Castano, Ana P. ;
Mroz, Pawel ;
Hamblin, Michael R. .
NATURE REVIEWS CANCER, 2006, 6 (07) :535-545
[6]   The quest to overcome resistance to EGFR-targeted therapies in cancer [J].
Chong, Curtis R. ;
Jaenne, Pasi A. .
NATURE MEDICINE, 2013, 19 (11) :1389-1400
[7]   Drug therapy: EGFR antagonists in cancer treatment [J].
Ciardiello, Fortunato ;
Tortora, Giampaolo .
NEW ENGLAND JOURNAL OF MEDICINE, 2008, 358 (11) :1160-1174
[8]   Antibody-drug conjugates in solid tumors: a look into novel targets [J].
Criscitiello, Carmen ;
Morganti, Stefania ;
Curigliano, Giuseppe .
JOURNAL OF HEMATOLOGY & ONCOLOGY, 2021, 14 (01)
[9]  
Dinu D, 2014, J Med Life, V7, P581
[10]   Extracellular region of epidermal growth factor receptor: a potential target for anti-EGFR drug discovery [J].
Dokala, A. ;
Thakur, S. S. .
ONCOGENE, 2017, 36 (17) :2337-2344